Urology Annals

ORIGINAL ARTICLE
Year
: 2021  |  Volume : 13  |  Issue : 3  |  Page : 199--204

Effect of preoperative finasteride on perioperative blood loss during transurethral resection of the prostate and on microvessel density in patients with benign prostatic hyperplasia: An open label randomized controlled trial


Uma Kant Dutt1, Sunil Kumar1, Lalgudi Narayanan Dorairajan1, Bhawana Ashok Badhe2, Ramanitharan Manikandan1, Suresh Singh1 
1 Department of Urology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
2 Department of Pathology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India

Correspondence Address:
Prof. Lalgudi Narayanan Dorairajan
Department of Urology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry - 605 006
India

Objective: Transurethral resection of the prostate (TURP) is a common procedure for the treatment of benign prostatic hyperplasia (BPH). Previous studies on the effect of 5-alpha reductase inhibitors on perioperative blood loss in TURP and microvessel density (MVD) in the prostate are equivocal. We evaluated whether pretreatment with finasteride for 2 weeks before surgery can reduce perioperative blood loss in TURP and MVD in the prostate. Materials and Methods: Sixty-eight patients of BPH planned for TURP were randomized into two groups. The study group comprising 34 patients was treated with finasteride (5 mg/day) for 2 weeks and the placebo group comprising 34 patients received placebo for 2 weeks, before TURP. Blood loss was measured in terms of a reduction in the blood hemoglobin (Hb) and hematocrit (HCT) levels between preoperative values and 24 h after surgery. MVD was measured in the resected prostate tissue stained with anti-CD31 monoclonal antibody. Results: The reduction of Hb and HCT in the finasteride group was significantly lower than the reduction in the placebo group (P < 0.05). The artery (P = 0.005), vein (P = 0.05), and gland (P = 0.008) densities were significantly less in the finasteride group than in the placebo group. There was no significant correlation between blood loss and MVD. Conclusions: Our study suggests a clear advantage of the preoperative use of finasteride for 2 weeks by reducing the perioperative blood loss in TURP in patients with BPH. While there is a significant reduction in MVD in the prostate on treatment with finasteride, it is not clear that this is the mechanism of reduction in blood loss in TURP.


How to cite this article:
Dutt UK, Kumar S, Dorairajan LN, Badhe BA, Manikandan R, Singh S. Effect of preoperative finasteride on perioperative blood loss during transurethral resection of the prostate and on microvessel density in patients with benign prostatic hyperplasia: An open label randomized controlled trial.Urol Ann 2021;13:199-204


How to cite this URL:
Dutt UK, Kumar S, Dorairajan LN, Badhe BA, Manikandan R, Singh S. Effect of preoperative finasteride on perioperative blood loss during transurethral resection of the prostate and on microvessel density in patients with benign prostatic hyperplasia: An open label randomized controlled trial. Urol Ann [serial online] 2021 [cited 2021 Jul 27 ];13:199-204
Available from: https://www.urologyannals.com/article.asp?issn=0974-7796;year=2021;volume=13;issue=3;spage=199;epage=204;aulast=Dutt;type=0